Thermo Fisher Scientific (NYSE:TMO) is set to release its earnings data before the market opens on Wednesday, April 25th. Analysts expect Thermo Fisher Scientific to post earnings of $2.40 per share for the quarter. Thermo Fisher Scientific has set its FY18 guidance at $10.68-10.88 EPS.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. Thermo Fisher Scientific’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.41 EPS. On average, analysts expect Thermo Fisher Scientific to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
Shares of TMO stock opened at $218.23 on Wednesday. The firm has a market cap of $86,122.42, a P/E ratio of 23.00, a PEG ratio of 1.58 and a beta of 1.14. Thermo Fisher Scientific has a twelve month low of $152.30 and a twelve month high of $226.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.34.
The company also recently disclosed a quarterly dividend, which was paid on Monday, April 16th. Investors of record on Thursday, March 15th were given a dividend of $0.17 per share. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.31%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s payout ratio is currently 7.17%.
A number of brokerages recently weighed in on TMO. Morgan Stanley reduced their price objective on Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 11th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $228.00 price objective on the stock in a research report on Tuesday, April 3rd. Leerink Swann restated an “outperform” rating and set a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Barclays boosted their price objective on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $220.64.
In other news, CEO Marc N. Casper sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total value of $8,406,400.00. Following the transaction, the chief executive officer now directly owns 334,622 shares of the company’s stock, valued at approximately $70,324,159.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William G. Parrett sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $209.80, for a total value of $209,800.00. The disclosure for this sale can be found here. Insiders sold a total of 88,827 shares of company stock worth $19,012,672 in the last quarter. Corporate insiders own 0.49% of the company’s stock.
An institutional investor recently raised its position in Thermo Fisher Scientific stock. Ark Investment Management LLC grew its holdings in Thermo Fisher Scientific (NYSE:TMO) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,005 shares of the medical research company’s stock after purchasing an additional 488 shares during the quarter. Ark Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $3,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 87.62% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://macondaily.com/2018/04/18/thermo-fisher-scientific-tmo-set-to-announce-earnings-on-wednesday.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.